Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting PRMT1 Reduces Cancer Persistence and Tumor Relapse in EGFR- and KRAS-Mutant Lung Cancer.

Cancer research communications - 1 Jan 2025

Sun Xiaoxiao, Kumbier Karl, Gayathri Savitha, Steri Veronica, Wu Lani F, Altschuler Steven J

Abstract excerpt

ABSTRACT: Incomplete killing of cancer cells undermines oncogene-targeting therapies and drives disease relapse. Eliminating cancer cells that persist during treatment is crucial for improving treatment outcomes. Here, we discovered that a specific isoform of type I protein arginine methyltransferases (PRMT), namely, PRMT1, enables lung cancer cells with EGFR or KRASG12C driver mutations and high STAT1 activity...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Neoplasm Recurrence, Local

Share to Protein-Arginine N-Methyltransferases

Share to Proto-Oncogene Proteins p21(ras)

Share to Repressor Proteins

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 39699269
DOI: 10.1158/2767-9764.CRC-24-0389
PMCID: PMC11747858

Genes

PRMT1
EGFR
KRAS
PRMT6
STAT1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting PRMT1 Reduces Cancer Persistence and Tumor Relapse in EGFR- and KRAS-Mutant Lung Cancer.PMID 39699269Read ↗

PRMT5 inhibitors actively promote metastatic progression of lung adenocarcinomaSemantic proximity Read ↗

TKI-Tolerant Persisters Emerge from a PKCα-Dependent and Highly Plastic Subpopulation of Stem-Like Cells in NSCLCSemantic proximity Read ↗

Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinomaSemantic proximity Read ↗

Elevated Expression of <i>MALAT1</i> Contributes to the Survival of Drug-Tolerant Persister Cells Following Targeted Therapy in Lung AdenocarcinomaSemantic proximity Read ↗

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.Semantic proximity Read ↗

H4K20me3-Mediated Repression of Inflammatory Genes Is a Characteristic and Targetable Vulnerability of Persister Cancer CellsSemantic proximity Read ↗

Local consolidative therapy after EGFR-TKI response in advanced EGFR-mutant NSCLC.Semantic proximity Read ↗

GSTA1 Conferred Tolerance to Osimertinib and Provided Strategies to Overcome Drug-Tolerant Persister in EGFR-Mutant Lung Adenocarcinoma.Semantic proximity Read ↗

Unearthing EGFR Mutations and the Rewards of Persistence in Precision Oncology: Breaching the 10-Year Survival Barrier in Metastatic NSCLC With Active Disease.Semantic proximity Read ↗

Reversible therapeutic resistance in <i>EGFR</i> mutant lung cancer caused by <i>RB1</i> loss induced lineage plasticitySemantic proximity Read ↗

ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts.Semantic proximity Read ↗

ResMap: A community resource for systematic mapping of therapy-persistent residual cancer cell dependencies across contexts.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.